

In re Application of:
Goggins and Ueki
Application No.: 10/084,555
Filed: February 25, 2002
Page 6

PATENT
ATTY. DOCKET NO.: JHU1700-1

REMARKS

By the present amendment, Applicants respectfully request incorporation of the attached Sequence Listing into the application. The specification has been amended to insert "SEQ ID NOS 106 through 114" into the Tables 3A and 3B on pages 53 and 54. SEQ ID NOS 106-114 are supported by the specification, as originally filed. Accordingly, no new matter has been added by the submission of the present amendments.

CONCLUSION

If the Examiner would like to discuss any of the issues raised in this Amendment or the attached sequence listing, Applicants' representative can be reached at (858) 677-1456.

Respectfully submitted,

Date: July 24, 2002



Lisa A. Haile, Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

USPTO Customer Number: 28213

EXHIBIT A
MARKED-UP COPY SHOWING AMENDMENTS TO SPECIFICATION

In the Specification:

The Tables 3A and 3B on pages 53, 54, 55 have been amended as follows:

TABLE 3A

PRIMER SEQUENCE FOR BISULFITE-SEQUENCE

<u>Clone</u>	<u>Orientation</u>	<u>Sequence</u>	<u>Annealing Temperature</u>	<u>SEQ ID NO:</u>
RARβ	Forward	5'-GAGTTGGTGTAGTTAGATTAG-3'	56	43
	Reverse	5'-TTCCCAAAAAATCCCAAATTC-3'		44
	Sequence	5'-CTCCTTCCAAATAAATACTTAC-3'		45
THBS1	Forward	5'-AGAGAGGAGTTTAGATTGG-3'	54	46
	Reverse	5'-CAAAAAAACTAAAACCTCAAC-3'		47
	Sequence	Forward primer		
CACNA1G	Forward	5'-	55, 53, 51, 49*	48
	Reverse	TGGATAAAGGATGTTTGGGGTTTG-		49
	Sequence	3'- 5'-CCCTCCCCTTACCCCTAAATCC-3' 5'-ACTCCCCCTCACTTTATTC-3'		50
hMLH1	Forward	5'-	58	51
	Reverse	ATTATTTTAGTAGAGGTATATAAG-		52
	Sequence	3'- 5'-CCAACCCCAACCTTCAAC-3' Forward primer		
MINT1	Forward	5'-AAGAGAGGGTTGGAGAGTAG-3'	62	53
	Reverse	5'-		54
	Sequence	CCCCTAAAAAAAATCAAAAATC- 3' 5'-GGGTTGGAGAGTAGGGGAGTT-3'		55
MINT2	Forward	5'-	60, 58, 56, 54**	56
	Reverse	YGTTATGATTTTTTTTGTAGTTAAT		57
	Sequence	-3' 5'-TACACCAACTACCCAACCTACCTC- 3' 5'-ACTTCCATTAAAAACAACCTAC-3'		106
MINT31	Forward	5'-	58	58
	Reverse	TTTATTTATATAATTTTGTGTATGG-		59
	Sequence	3'- 5'-CACCCCTCACTTTACTAAAAC-3' Reverse primer		
MINT32	Forward	5'-TTTGGGAGGTAAATTYGTTGATT-	58, 56, 54, 52***	60
	Reverse	3'-		61
	Sequence	5'- ACCRAACAAAAACCTAAAAAAC- 3' Forward primer		

* 55 (5 cycles), 53 (5 cycles), 51 (5 cycles), 49 (26 cycles)

** 60 (3 cycles), 58 (4 cycles), 56 (5 cycles), 54 (26 cycles)

*** 58 (3 cycles), 56 (4 cycles), 54 (5 cycles), 52 (26 cycles)

TABLE 3B-PRIMER SEQUENCES FOR MSP

Clone	Orientation & Methylation	Sequence	Annealing Temperature	SEQ ID NO:
P16	Unmethylated	F 5'-TTATTAGAGGGTGGGGTGGATTGT-3'	60	62
		R 5'-CAACCCCAAACCCACAACCATAA-3'		107
	Methylated	F 5'-TTATTAGAGGGTGGGGCGGATCGC-3'	65	63
		R 5'-GACCCCGAACC GCGACCTAA-3'		108
RARβ	Unmethylated	F 5'-AGGATTGGGATGTTGAGAATG-3'	58	64
		R 5'-TTACAAAAACCTTCCAAATACA-3'		109
	Methylated	F 5'-GGATTGGGATGTCGAGAAC-3'	64	65
		R 5'-TACAAAAACCTTCCGAATACG-3'		110
CACNA1G	Unmethylated	F 5'-GTTTTTTTTTGGATTTTGTITTTTG-3'	60	66
		R 5'-TTTATTCCAACCTCTTCACTTCA-3'		111
	Methylated	F 5'-GTTTTTTCGGGCGGTTTC-3'	62	67
		R 5'-TTCCGACTTCTTCGCTTCG-3''		112
TIMP-3	Unmethylated	F 5'-	59	68
		R TTTTGTTTTGTTATTTTTTGTTTTGGTTTT		
	Methylated	F -3	59	69
		R 5'-CCCCCAAAAACCCACCTCA-3'		
THBS1	Unmethylated	F 5'-GTTTGTTGTTGTTTATTGGTTG-3'	62	70
		R 5'-CCTAAACTCACAAACCAACTCA-3'		71
	Methylated	F 5'-TGCGAGCGTTTTTTTAAATGC-3'	62	72
		R 5'-TAAACTCGCAAACCAACTCG-3'		73
HMLH1	Unmethylated	F 5'-TTAATAGGAAGAGTGGATAGTG-3'	56	74
		R 5'-TCTATAAAATTACTAAATCTCTTCA-3'		75
	Methylated	F 5'-TTAATAGGAAGAGCGGATAGC-3'	58	76
		R 3'-CTATAAAATTACTAAATCTCTTCG-3'		77
E-Cad	Unmethylated	F 5'-TAATTTTAGGTTAGAGGGTTATTGT-3'	53	78
		R 5'-CACAACCAATCAACAACACA-3'		79
	Methylated	F 5'-TTAGGTTAGAGGGTTATCGCGT-3'	57	80
		R 5'-TAACTAAAATTACCTACCGAC-3'		81
DAPK	Unmethylated	F 5'-GGAGGATAGTTGGATTGAGTTAATGTT-3'	60	82
		R 5'-CAAAATCCCTCCCAAACACCAA-3'		83
	Methylated	F 5'-GGATAGTCGGATCGAGTTAACGTC-3'	60	84
		R 5'-CCCTCCCAAACGCCGA-3'		85
MGMT	Unmethylated	F 5'-	59	86
		R TTTGTGTTTTGATGTTTGTAGGTTTTGT-3'		87
	Methylated	F 5'-	59	88
		R AACTCCACACTCTTCCAAAAACAAAACA-3'		89
		F 5'-TTTCGACGTTTCGTACCTTTTCGC-3'		
		R 5'-GCACTCTCCGAAAACGAAACG-3'		

MINT1	Unmethylated	F	5'-GGGGTTGAGGTTTTTTGTTAGT-3'	64	90
		R	5'-TTCACAACCTCAAATCTACTTCA-3'		91
	Methylated	F	5'-GGGTTGAGGTTTTTTGTTAGC-3'	64	92
		R	5'-CTACTTCGCCTAACCTAACG-3'		93
MINT2	Unmethylated	F	5'-GGTGTTGTAAATGTAAATAATTTG-3'	58	94
		R	5'-AAAAAAAAACACCTAAACTCA-3'		95
	Methylated	F	5'-AATCGAATTTGTCGTCGTTTC-3'	60	96
		R	5'-AAATAAAATAAATAAAAAAAAAACGCG-3'		97
MINT31	Unmethylated	F	5'-GAATTGAGATGATTTTAATTTTGT-3'	64	98
		R	5'-CTAAAACCATCACCCCTAAACA-3'		99
	Methylated	F	5'-TTGAGACGATTTTAATTTTTC-3'	62	100
		R	5'-AAAACCATCACCCCTAAACG-3'		101
MINT32	Unmethylated	F	5'-GAGTGGTTAGAGGAATTTAGGT-3'	62	102
		R	5'-CTAAAAAAACAAACAAAACATCCA-3'		103
	Methylated	F	5'-GTGGTTAGAGGAATTTAGGC-3'	64	104
		R	5'-AAAACGAACGAAACGTCCG-3'		105